Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Google Scholar citation report
Citations : 1529
Journal of Infectious Diseases & Therapy received 1529 citations as per Google Scholar report
Indexed In
- Index Copernicus
- Google Scholar
- Open J Gate
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
Controlling viral infection with Metadichol
2nd International Conference on Influenza
Palayakotai Raghavan
Nanorx Inc., USA
Keynote: J Infect Dis Ther
Abstract
Metadichol (US patent 8,722,093) is a nano-emulsion of long-chain alcohols found in many foods. It is commonly called Policosanol and is present in foods such as rice, sugar cane, wheat, peanuts. Metadichol acts on Nuclear Vitamin D receptors (VDR) (US patent 9,006,292) that are present in cells throughout the body to stimulate the immune system and inhibit a variety of disease processes, resulting from viral infections. We tested for antiviral activity of Metadichol�® in Vero and MDCK cells infected with Influenza A, H1N1, Human Respiratory Syncytial virus, Dengue, Chikungunya and Ebola, Marburg. In addition, we tested the efficacy of Metadichol�® in preventing cell death caused by Adenovirus, Tacaribe Mammarena virus, Rift Valley Fever virus, SARS coronavirus, Japanese Encephalitis virus, West Nile virus, and Yellow Fever virus. In the in vitro assays, Metadichol showed no cytotoxicity and strongly inhibited cell death caused by each of the viruses tested. Metadichol is a safe and effective inhibitor of enveloped viruses in humans. Since it is known to bind to the vitamin D receptor (VDR) (US patent 9,006,292), its mechanism of action likely involves the competitive displacement of virus particles from VDRâ��s on host cell membranes. Because it consists of natural components of common foods and has no known negative side effects, Metadichol has the potential to serve as a novel, broad-spectrum antiviral treatment for Dengue, Ebola, Zika, H1N1, SARS, Chikungunya and other enveloped viruses.Biography
Palayakotai Raghavan is the CEO and Founder of Nanorx Inc., New York, USA. He has completed his PhD in Organic Chemistry from Oregon State University in 1979 and MS in Chemistry in 1972 from IIT Mumbai, India. He has worked on drug discovery for over 25 years at Columbia University, Max-Planck Institute, Germany, Ciba-Geigy (now Novartis) and Boehringer Ingelheim. He has over 12 patents and another 15 pending patent applications.
Email: raghavan@nanorxinc.com
